Skip to main content
Bulletin of the World Health Organization logoLink to Bulletin of the World Health Organization
. 1984;62(4):585–590.

The effect of immune globulin on the response to trivalent oral poliovirus and yellow fever vaccinations

Jonathan E Kaplan, David B Nelson, Lawrence B Schonberger, Milford H Hatch, Thomas P Monath, John S Lazuick, Charles H Calisher, Franz W Rosa
PMCID: PMC2536331  PMID: 6333295

Abstract

To assess whether immune globulin may be administered concurrently with trivalent oral poliovirus vaccine (OPV) or yellow fever vaccine, antibody responses were studied in Peace Corps volunteers embarking for overseas duty in 1978. Of 200 volunteers who received OPV, 192 (96%) had pre-existing neutralizing antibody to at least 2 poliovirus types; of 160 yellow fever vaccinees, 24 (15%) had pre-existing 17D yellow fever antibody. Each volunteer received 5 ml of immune globulin, 0-7 days before, 3-5 days after, or 28-32 days after vaccination. This last group was designated the control group. Of the volunteers who received immune globulin 0-7 days before vaccination, 71% 72%, 49%, and 82% responded to poliovirus types 1, 2, and 3, and yellow fever, respectively (response was defined as a 4-fold or greater rise in serum neutralizing antibody titre between baseline (0-7 days before vaccination) and follow-up (15-40 days after vaccination)). These rates did not differ significantly from those in persons who received immune globulin 28-32 days after vaccination (61%, 60%, 51%, and 83%, respectively). Thus, among individuals who, for the most part, were immune to poliomyelitis but not to yellow fever, immune globulin did not decrease the antibody response to OPV or to yellow fever vaccine when given 0-7 days before vaccination.

Full text

PDF
585

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Felsenfeld O., Wolf R. H., Gyr K., Grant L. S., Dutta N. K. Simultaneous vaccination against cholera and yellow fever. Lancet. 1973 Mar 3;1(7801):457–458. doi: 10.1016/s0140-6736(73)91882-5. [DOI] [PubMed] [Google Scholar]
  2. Gateff C., Le Gonidec G., Boche R., Sarrat P., Lemarinier G., Monchicourt D., Labusquière R. Influence de la vaccination anticholérique sur l'immunisation antiamarile associée. Bull Soc Pathol Exot Filiales. 1973 Mar-Apr;66(2):258–266. [PubMed] [Google Scholar]
  3. KRUGMAN S., GILES J. P., JACOBS A. M., FRIEDMAN H. Studies with a further attenuated live measles-virus vaccine. Pediatrics. 1963 Jun;31:919–928. [PubMed] [Google Scholar]
  4. Painter R. H., Weber J. C., Wardlaw A. C. Antitoxic and antiviral antibodies in Cohn fractions of human plasma. Clin Exp Immunol. 1968 Feb;3(2):179–187. [PMC free article] [PubMed] [Google Scholar]
  5. Poland J. D., Calisher C. H., Monath T. P., Downs W. G., Murphy K. Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine. Bull World Health Organ. 1981;59(6):895–900. [PMC free article] [PubMed] [Google Scholar]
  6. ROSENBAUM M. J., PHILLIPS I. A., SULLIVAN E. J., EDWARDS E. A., MILLER L. F. A simplified method for virus-tissue culture procedures in microtitration plates. Proc Soc Exp Biol Med. 1963 May;113:224–229. doi: 10.3181/00379727-113-28325. [DOI] [PubMed] [Google Scholar]

Articles from Bulletin of the World Health Organization are provided here courtesy of World Health Organization

RESOURCES